Aktuella utlysningar, vecka 47, 2021
Grants Office tipsar om aktuella utlysningar
Svenska och nordiska anslag
Forskningsstipendier - Maud & Birger Gustavssons Stiftelser
Stöder forskning och utbildning inom olika områden av medicin, i första hand inom urologisk kirurgi, samt utvecklingsarbete för att förebygga och lindra sjukdom bland barn i utvecklingsländer. Dessutom stöder stiftelserna forskning och utbildning inom ekonomisk information för att främja en hög standard hos svenska journalister.
Closing date: 31 December 2021
Methodological studies and educational courses - Swedish Childhood Cancer Foundation
Enables researchers within the area of paediatric oncology to take up studies and educational courses abroad for up to three months. Grants are generally intended to fully or partly cover low-price return tickets, housing cost and return transfer tickets.
Closing date: 17 January 2022
EFSD and Novo Nordisk A/S Programme for Diabetes Research in Europe
Support initiatives in all areas of diabetes research, including both basic and clinical research. Grants are worth up to €100,000 each.
Closing date: 1 February 2022
Janne Carlssons stipendium för akademiskt ledarskap
Stipendiet syftar till att stimulera verksamma personer inom den svenska akademiska världen att utveckla sitt akademiska ledarskap.
Stipendiet tilldelas person eller personer som under föregående år gjort framträdande insatser inom akademiskt ledarskap, speciellt genom att utveckla samarbets-/samverkansformer inom högskolevärlden och mellan denna och samhälle/industri inom landet. Prissumman uppgår till 100 000 kr.
Nomineringar kan lämnas av akademiska och forskningsstödjande organisationer såsom universitet/högskolor, stiftelser, företag och andra organisationer.
Nomineringsperioden för 2021 avslutas 21 januari 2022.
Läs mer och nominera kandidater: Janne Carlssons stipendium för Akademiskt ledarskap | KTH
För frågor och mer information kontakta KTH:s ledningskansli via email@example.com
ASPIRE global cachexia grant. Pfizer, INT
Pfizer, under its competitive grant programme, invites applications for its ASPIRE global cachexia grant. This supports research to gain a better understanding of the relationship between cachexia and cancer or heart failure. Basic science, preclinical research, and clinical research, animal experimentation related to human biology, and translational studies in the following topics will be considered:
•evidence generation in understanding cachexia in cancer or heart failure;
•the role of GDF-15/GFRAL pathway in disease;
•GDF-15/GFRAL biology; and
•natural history or longitudinal studies specifically related to cachexia or heart failure.
Eligibility: • Only organizations are eligible to receive grants, not individuals or medical practice groups. • The applicant (PI) must have a medical or postdoctoral degree (MD, PhD, or equivalent), an advanced nursing degree (BSN with a MS/PhD), or a degree in Pharmacy, Physiotherapy, or Social Work. • Applicant must be affiliated with a host institution. • Both early career and experienced investigators are encouraged to apply and consideration will be given to all proposals meeting the selection criteria.
Budget: Grants are worth up to USD 250,000 for up to three years.
Deadline: Full Proposal Due Date: *January 7, 2022 *[Please note the deadline is 23:59 Eastern Time (New York, GMT -5).]
EFSD and Novo Nordisk A/S Programme for Diabetes Research in Europe
The European Foundation for the Study of Diabetes and Novo Nordisk invite applications for their diabetes research in Europe programme. This supports initiatives in all areas of diabetes research in order to rapidly diffuse acquired knowledge and to facilitate its application.
Applications are invited from single non-profit institutions or groups of such institutions from Europe and associated countries and the study must be performed at their place of work.
Budget: Grants are generally worth up to €100,000 each for both basic research projects and clinical research projects. Applications with a funding requirement larger than this may be considered. The duration of the project may be one year or longer depending on the project.
Deadline: 1 February 2022, 12:00 midday (CET)
EFSD/Lilly young investigator research awards. European Association for the Study of Diabetes, EUR
The European Foundation for the Study of Diabetes and Lilly invite applications for their young investigator research awards. These encourage innovative research in the field of diabetes and its complications, and promote excellence in medical education.
Eligibility: Applicants must be paid-up members of EASD and must have received their highest degree no more than five years ago for basic scientists, or seven years ago for clinicians on 1 January 2022. For clinicians holding more than one qualifying degree or with a clinical specialist degree, the time since the first degree must be no more than 10 years before January 1 2022. Research awards must be held at a non-profit institution based in Europe or an associated country.
Budget: Awards are worth €50,000 each.
Deadline: 15 February 2022. 12:00 midday (CET).
Federal Funding agencies
Understanding the role of bilingualism in cognitive reserve/resilience in ageing and AD/ADRD (R01 clinical trial optional), NIH
The goal of this Funding Opportunity Announcement (FOA) is to support research studying the role of bilingualism as it relates to cognitive reserve/resilience in healthy aging and in Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD). This FOA aims to address the need for more prospective, hypothesis-driven research to build a theoretical framework and to clearly identify the extent to which acquiring a second language impacts human brain function. Multimodal and multidisciplinary studies are highly encouraged to improve our understanding of the complex interactions between neural, environmental, and sociocultural factors and the role of bilingualism in healthy aging and in AD/ADRD.
Deadline: March 04, 2022. Letter of Intent Due Date: February 1, 2022. All applications are due by 5:00 PM local time of applicant organization.
Funding Opportunity Announcement (FOA): RFA-AG-23-001
Further information: RFA-AG-23-001: Understanding the Role of Bilingualism in Cognitive Reserve/Resilience in Aging and AD/ADRD (R01 Clinical Trial Optional) (nih.gov)
Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional), NIH
This funding opportunity announcement (FOA) encourages applications for research in cancer control and population sciences. The overarching goal is to provide support to promote research efforts on novel scientific ideas that have the potential to substantially advance cancer research in statistical and analytic methods, epidemiology, cancer survivorship, cancer-related behaviors and behavioral interventions, health care delivery, and implementation science.
Deadline: March 07, 2022; November 8, 2022; March 07, 2023; November 5, 2023; March 7, 2024. All applications are due by 5:00 PM local time of applicant organization.
Funding Opportunity Announcement (FOA): PAR-21-190
The Autoantigens and Neoantigens Function in the Etiology and Pathophysiology of Type 1 Diabetes (R01 Clinical Trial Optional), NIH
This Funding Opportunity Announcement (FOA) encourages applications from institutions and organizations proposing original research aimed at the characterization of the function of neoepitopes and neoantigens in type 1 diabetes. This includes the function that post-translational modifications might have in the humoral and cell mediated autoimmune responses and overall in the etiology and pathophysiology of type 1 diabetes. Applications that include the discovery of neoantigens or neoepitopes are within the scope of this solicitation, but should propose a plan for integrating these discoveries with the present knowledge on established epitopes and antigens (e.g. autoantibodies for insulin, GAD65, IA-2, and ZnT8). In the long-term the goals of this initiative are to facilitate the development of better tools to monitor disease progression and treatment, and potentially to facilitate the development of personalized therapeutics.
Deadline: March 10, 2022. Letter of Intent Due Date: February 09, 2022. All applications are due by 5:00 PM local time of applicant organization.
Funding Opportunity Announcement (FOA): RFA-DK-21-004
Extracellular RNA carrier subclasses in processes relevant to Substance Use Disorders or HIV infection (R21- Clinical Trial Not Allowed), NIH
The purpose of this FOA is to encourage research investigating the roles of extracellular RNA (exRNA) carrier subclasses in biological processes relevant to substance use disorders (SUDs) and/or HIV infection, latency, or pathogenesis in the CNS. Applicants may propose to investigate biological mechanisms involving exRNA carrier subclasses, or propose to develop improved technologies to investigate extracellular vesicles or other exRNA carriers.
Deadline: March 15, 2022, October 13, 2022, March 15, 2023. All applications are due by 5:00 PM local time of applicant organization.
Funding Opportunity Announcement (FOA): PAR-20-148
Research grants - North American Spine Society, US
The North American Spine Society invites letters of proposal for its research grants. These support basic, clinical or translational research projects in spine-related specialties. Qualified applicants from any field and of any nationality may apply. The principal investigator must be a member of the society. New investigators are especially encouraged to apply. Medical residents may apply provided that they have a mentor or faculty support.
Grants are generally worth between USD 20,000 and USD 40,000 per year for one to two years. In rare cases, grants may be worth up to USD 50,000 per year. Cost sharing is encouraged.
Deadline: Letter of Proposal: February 7, 2022; Grants (By Invitation Only): May 9, 2022.
Further information: 2022 Research Funding Application (spine.org)
Clinical pilot and feasibility award - Cystic Fibrosis Foundation, US
The Cystic Fibrosis Foundation invites letter of intent for its clinical pilot and feasibility award. The intent of the Clinical Pilot and Feasibility Award is to enable investigators to collect sufficient preliminary data to determine the best strategies and methods for approaching a major question that ultimately will require assessment through a larger scale research and/or multi-center, collaborative clinical trial. Special consideration will be given to those projects that pursue new approaches, study under-researched topics, or investigate more creative avenues of research to address the problems of cystic fibrosis. Applications for continued funding of existing projects, or for long-term support of an investigator, will not be considered.
Priority is given to the following areas: respiratory micro-organism detection and treatment; gastrointestinal symptoms; reducing treatment burden; cystic fibrosis-related diabetes; diet and nutrition; mental health; cystic fibrosis-related liver disease; exercise; sinus disease; allergies and asthma; alternative or holistic treatments and therapies; sexual reproductive health; bone or joint health; pain management.
Applicants must be independent investigators. Fellows may submit applications provided they hold a faculty-level appointment at the time of the award.
Awards are worth USD 80,000 each per year for a maximum period of two years.
Deadline: Letter of Intent: March 28, 2022; Full Application: August 8, 2022.
Further information: Clinical Pilot and Feasibility Awards | CF Foundation
Postdoctoral research award - Friedreich’s Ataxia Research Alliance, US
FARA offers a Postdoctoral Research Award as a mechanism to expand and retain young investigators in the FA biomedical research space. For this application type, the Postdoctoral trainee is the PI of the grant proposal. Postdoctoral trainees should focus their research proposal on projects that fall within FARA Research Priorities, as outlined here. Applicants are required to submit a personal statement describing their current position and plans for the future as it relates to FA research, with a description of career goals and how the proposed research and research environment will favor achieving those goals. A mentoring plan developed jointly by the junior investigator and mentor(s), as well as letters of support from all mentors are also required. Competitive candidates demonstrate qualities that will enhance FARA's overall enterprise of understanding fundamentals of disease pathology and developing treatments and a cure for FA.
Deadline: Letter of Intent (LOI) Deadline: February 1 and July 15, 2022; Application Deadline: April 1 and September 15, 2022.
Further information: FARA - Grant Program (curefa.org)
Irvington postdoctoral fellowships - Cancer Research Institute, US
The Cancer Research Institute invites applications for the Irvington postdoctoral fellowships. These support young scientists at universities and research centres worldwide who wish to receive training in cancer immunology. Projects should be hypothesis driven, mechanistic studies in both immunology and tumour immunology that directly impact understanding of the immune system’s role in cancer.
Applicants must be working in areas directly related to immunology or cancer immunology. They must have a doctoral degree and less than five years’ relevant postdoctoral experience, with the exception of MD applicants. Projects must be conducted under a sponsor who holds a formal appointment at the host institution. The fellowship may be taken in the US or abroad, but must be conducted at a non-profit institution. There are no citizenship restrictions.
Fellowships are worth USD 175,500 each over three years. Funding may cover salary, health insurance, travel expenses and other research-related costs. Deductions for administrative overhead are not allowed.
Deadline: March 1 and October 1, 2022. Applications are due by 5 p.m. Eastern Time.
Further information: CRI Irvington Postdoctoral Fellowships - Cancer Research Institute